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The transcription factor PU.1 plays multiple context
and concentration dependent roles in lymphoid and
myeloid cell development. Here we showed that
PU.1 (encoded by Sfpi1) was essential for dendritic
cell (DC) development in vivo and that conditional
ablation of PU.1 in defined precursors, including
the common DC progenitor, blocked Flt3 ligand-
induced DC generation in vitro. PU.1 was also
required for the parallel granulocyte-macrophage
colony stimulating factor-induced DC pathway from
early hematopoietic progenitors. Molecular studies
demonstrated that PU.1 directly regulated Flt3 in
a concentration-dependent manner, as Sfpi1+/ cells
displayed reduced expression of Flt3 and impaired
DC formation. These studies identify PU.1 as a criti-
cal regulator of both conventional and plasmacytoid
DC development and provide one mechanism how
altered PU.1 concentration can have profound
functional consequences for hematopoietic cell
development.
INTRODUCTION
The ETS family transcription factor PU.1 plays multiple roles in
hematopoiesis. PU.1 (encoded by the gene Sfpi1) regulates
numerous genes within the myeloid and lymphoid lineages,
including those encoding the developmentally important cyto-
kine receptors, macrophage colony stimulating factor receptor
(M-CSFR), granulocyte-macrophage colony stimulating factor
receptor (GM-CSFR), and the interleukin 7 receptor (IL-7R,
reviewed in Dakic et al., 2007). Mice with Sfpi1 germline muta-
tions have profound impairment in hematopoiesis and die either
in late gestation or shortly after birth (McKercher et al., 1996;
Scott et al., 1994). In contrast, enforced expression of Sfpi1 in
hematopoietic progenitors suggests an instructive and concen-
tration-dependent role of PU.1 in promoting macrophage and
dendritic cell (DC) development (Bakri et al., 2005; DeKoter
and Singh, 2000; Laiosa et al., 2006; Nerlov and Graf, 1998;628 Immunity 32, 628–641, May 28, 2010 ª2010 Elsevier Inc.Spooner et al., 2009). Studies usingmicewith either a conditional
mutation that allows inactivation of Sfpi1 in adult hematopoietic
cells or with reduced Sfpi1 expression throughout adult hemato-
poiesis demonstrated that PU.1 deficiency resulted in dramati-
cally perturbed hematopoiesis and greatly enhanced granulo-
poiesis (Dakic et al., 2005; Houston et al., 2007; Iwasaki et al.,
2005; Rosenbauer et al., 2004). Analysis of the multipotent
progenitors revealed that PU.1 ablation led to the loss of all
identifiable lymphoid and myeloid progenitor populations and
long-term multilineage repopulating hematopoietic stem cell
(HSC) activity (Dakic et al., 2005; Iwasaki et al., 2005). These
findings demonstrate that PU.1 is required for the maintenance
of normal HSC function and the regulation of commitment of
adult hematopoietic progenitors.
The concentration-dependent functions of PU.1 in cell-fate
decisions are mirrored by the dynamic nature of Sfpi1 expres-
sion during hematopoiesis. Using PU.1-GFP reporter mice, we
and others have demonstrated that within adult hematopoietic
progenitors, Sfpi1 is highly expressed in the HSCs and the
earliest myeloid and lymphoid progenitors but is downregulated
in megakaryocyte-erythrocyte lineage precursors (Back et al.,
2005; Nutt et al., 2005). Upon lineage commitment, Sfpi1 is
expressed highly by myeloid cells, at low amounts by B cells,
and is silenced in the erythrocytic lineage, in mature NK cells
and in developing thymocytes. Within the DC lineage, Sfpi1sh-
ows a bimodal expression pattern, being highly expressed by
conventional DCs (cDCs) but present in low amounts in plasma-
cytoid DCs (pDCs) (Back et al., 2005; Nutt et al., 2005).
DCs are bone marrow (BM)-derived antigen-presenting cells
of the immune system that play important roles in regulating
immune responses. Studies on the developmental origin of
DCs showed that both cDCs and pDCs could be generated by
Flt3-expressing myeloid or lymphoid progenitors, as well as by
the common DC progenitors (CDPs) (D’Amico and Wu, 2003;
Karsunky et al., 2003; Naik et al., 2007; Onai et al., 2007). Flt3
is a receptor tyrosine kinase that is expressed on a subset of
multipotent progenitors. Mice with a deficiency in Flt3 or Flt3
ligand (Flt3L) exhibited reduced DC numbers (McKenna et al.,
2000; Waskow et al., 2008), whereas mice treated with Flt3L
showed a dramatic increase in DC numbers (Maraskovsky
et al., 1996). These observations indicate an essential role of
Flt3 in steady-state DC development; however, the regulation
of Flt3 expression remains poorly understood.
Figure 1. Expression of PU.1 by Mouse DC Populations
(A and B) Splenic DCs (A) and Flt3L BM cell cultures (B) were analyzed by flow cytometry for the expression of PU.1-GFP in gated cDC (CD11chiCD45RA) and
pDC (CD11cintCD45RA+) populations.
(C) CDPs were identified from Lin BM as Flt3+c-kitlo (left panel) and CD115+CD11c (middle panel) and analyzed for PU.1-GFP.
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PU.1 Is Required for Dendritic CellsAlthough a growing number of transcription factors, including
Irf8, Batf3, RelB, E2-2, Id2, Ikaros, Gfi-1, STAT3, and STAT5,
have been implicated in the development and/or homeostasis
of specific DC populations, no transcription factor has been
shown to be required for all DC lineages (reviewed in Merad
and Manz, 2009; Wu and Liu, 2007). PU.1 is an attractive candi-
date as a crucial regulator of the DC lineages because it is
expressed in all cDCs and pDCs (Back et al., 2005; Nutt et al.,
2005). Indeed, earlier studies of PU.1-deficient mice showed
defects in DC development (Anderson et al., 2000; Guerriero
et al., 2000); however, the early lethality of these mutant mice
precluded investigation of the role of PU.1 in DC development
in adult mice. Thus, it was unknown whether PU.1 functions
within the DC lineage or whether, as is the case for B-lympho-
cytes (Iwasaki et al., 2005; Polli et al., 2005; Ye et al., 2005), it
is only essential for the formation of earlier hematopoietic
progenitors. In this study, we aimed to determine whether
PU.1 was required for DC development in adult mice and, if so,
at which developmental stage PU.1 acted. We provide strong
evidence that PU.1 is an essential regulator of both cDC and
pDC lineages. Furthermore, we demonstrate that PU.1 controls
DC development in part through direct regulation of the gene
encoding the important cytokine receptor, Flt3. The reduced
Flt3 expression in Sfpi1+/D progenitors corresponds with
reduced production of cDCs in vitro, demonstrating that the
regulation of Flt3 represents one of the mechanisms by which
distinct PU.1 concentrations control hematopoietic cell-fate
decisions.
RESULTS
PU.1 Expression in DCs
To track Sfpi1 expression by cDCs and pDCs, we have utilized
Flt3L supplemented BM cultures of cells derived from PU.1-
GFP knockin mice (Naik et al., 2005; Nutt et al., 2005). In vitro
generated cDCs and pDCs expressed similar amounts of
PU.1-GFP to those isolated from spleen (Figures 1A and 1B).
CDPs, identified as lineage marker negative (Lin) c-kitintFlt3+
CD115+CD11c (Naik et al., 2007; Onai et al., 2007), were uni-
formly PU.1-GFPhi (Figure 1C), suggesting that Sfpi1 is specifi-
cally downregulated in pDCs. To investigate the onset of pDC
differentiation, sorted CDPs were cultured in the presence of
Flt3L and changes in PU.1-GFP were tracked over time. By
day 2, a substantial proportion of CDPs upregulated CD11c
expression while maintaining high expression of PU.1-GFP.
Beginning day 3, approximately 10% of the CD11c+ cells initi-
ated CD45RA expression and simultaneously downregulated
CD11c and PU.1-GFP to produce CD45RA+CD11cintPU.1-
GFPint pDCs, whereas the remaining cells maintained high
PU.1-GFP and differentiated into CD45RACD11c+PU.1-GFPhi
cDCs (Figure 1D). By day 4, the majority of cells became
CD11c+PU.1-GFPhi cDCs, while 10% cells were CD11cintPU.1int
pDCs (Figure 1D). Hence, the divergence of the cDC and pDC
lineages is closely paralleled by altered PU.1 concentrations.(D) Purified CDPs were cultured in the presence of Flt3L and Ly5.1 BM feeder cells
cytometry on days 2, 3, and 4. The dotted lines represent negative controls for PU
and the solid lines represent the PU.1-GFP expression on corresponding cells fr
experiments.
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of PU.1 in Adult Hematopoietic Cells
To study the importance of PU.1 in DC development in adult
mice, we induced PU.1-inactivation by treatment of adult
Sfpi1fl/flMx1Cre+ and control Sfpi1fl/fl mice with two intraperito-
neal injections of polyIC (days 0 and 3). Treated mice were
analyzed 10–12 days later. We have previously shown that
this treatment regime induces virtually complete inactivation of
PU.1 in BM and spleen (Dakic et al., 2005). Analysis of the DC
populations in the thymus and spleen of treated mice showed
that the numbers of both cDCs and pDCs were drastically
reduced in the absence of PU.1 (Figures 2A and 2B). Further
phenotypic analysis using a combination of different cell-surface
molecules, including MHC-II, CD8, and CD205 (as indicated by
the boxes in Figure 2A), confirmed the near absence of these
DC populations, and the lack of expression of these molecules
by PU.1-deficient cells excluded the possibility that the loss of
DCs was because of the lack of expression of CD11c.
Cell Intrinsic Defect in DC Generation
in the Absence of PU.1
To determine whether the defect in DC development in PU.1-
deficient mice is cell intrinsic, Lin BM cells from either polyIC-
treated Sfpi1fl/flMx1Cre+ mice or control mice (both Ly5.2+)
were injected intravenously, together with total BM cells of the
host type (Ly5.1+), into lethally irradiated Ly5.1+ recipients. Three
weeks later, donor derived cells (identified as Ly5.1) in the
spleen of the recipient mice were analyzed. In contrast to the
control cells, which produced lymphocytes,macrophages, gran-
ulocytes, cDCs, and pDCs, PU.1-deficient Lin BM cells
produced only Gr-1+ granulocytes (Figure S1A available online).
Similar results were obtained when PU.1-deficient Lin spleno-
cytes were used as a source of progenitors (Figure S1B),
excluding the possibility that the precursor cells had migrated
to the spleen.
The capacity of PU.1-deficient BM cells to differentiate into
DCs was further tested in vitro. BM cells from Sfpi1fl/flMx1Cre+
(Ly5.2+) or control (Sfpi1fl/fl) mice were mixed with equal number
of Ly5.1+ BM cells and analyzed for cDC and pDC development
after 9 days culture in Flt3L. PU.1-deficient BM cells failed to
generate any cDCs or pDCs in these cultures (Figure 2C). Taken
together, these results demonstrate an intrinsic requirement
for PU.1 in DC precursors for the generation of both cDCs
and pDCs.
PU.1 Is Required for Flt3L-Induced DC Development
from Hematopoietic Precursors
As DCs can be generated fromHSCs and from Flt3+ myeloid and
lymphoid-committed precursors (D’Amico and Wu, 2003), all of
which express Sfpi1, it was not clear whether the defect in DC
development in PU.1-deficient mice resulted from a deficiency
in themaintenance of HSC function or whether PU.1 was directly
required for DC development by these precursors. To answer
this question, we crossed Sfpi1fl/fl mice with those harboring, and the expression of PU.1-GFP, CD11c, and CD45RA was analyzed by flow
.1-GFP expression by cDCs, pDCs, and CDPs from C57BL/6 wild-type mice,
om Sfpi1fl-gfp/fl-gfp mice. Data are representative of at least three independent
Figure 2. Drastically Reduced Numbers of cDCs and pDCs in PU.1-Deficient Mice
(A) Sfpi1fl/flMx1Cre+ and Sfpi1fl/fl control mice were injected with polyIC on days 0 and 3 and analyzed by flow cytometry after 2 weeks. Flow cytometry of purified
DC preparations from the spleens of mice of the indicated genotypes. Boxes are used as a guide to indicate the position of the DC populations in control mice.
(B) Absolute numbers of cDCs and pDCs were calculated from percentages of the cell populations defined as in (A, left panels) from total splenocytes and thymo-
cytes. The numbers of cDC and pDC represent mean ± SD from three experiments. p values compare the indicated groups using a paired t test (one-tailed).
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PU.1 Is Required for Dendritic CellsaCreERtm transgene. This genotype brings Cre activity, and thus
inducible PU.1 inactivation, under the control of the drug tamox-
ifen. Precursor populations were isolated from the BM of these
mice and cultured in the presence of Flt3L and Ly5.1+ BM feeder
cells. Whereas unfractionated BM cells from Sfpi1fl-gfp/fl-gfp
CreERtm+ (see Experimental Procedures for a full description of
the Sfpi1 alleles used in this study) mice generated abundant
DCs (Ly5.2+CD11c+ or GFP+CD11c+) when cultured in the pres-
ence of Flt3L for 9 days, parallel cultures that contained tamox-
ifen produced very few DCs (Figures S2A and S2B). In keeping
with this phenotype, genotyping analysis showed efficient dele-
tion of exon 5 ofSfpi1 in the presence of Cre activity (Figure S2C).
The BM cells from Sfpi1fl-gfp/fl-gfp control mice showed no differ-
ence in DC production with or without tamoxifen, indicating that
the lack of DC production from PU.1-deficient BM cells in the
presence of tamoxifen was not simply because of the cytotox-
icity of the drug (Figures S2A and S2B). The failure of DC produc-
tion in the absence of PU.1 was not the consequence of impaired
cell survival, as germline-deleted Sfpi1D/D fetal liver cells were
unable to differentiate into DCs in Flt3L cultures regardless of
the presence of a vav-Bcl2 transgene that blocked apoptosis
(Figure S2D).
Using this in vitro system for PU.1 inactivation, we further
examined the requirement of PU.1 for DC development from
purified LinSca-1+c-kit+ (LSK) cells, common lymphoid pro-
genitors (CLPs), common myeloid progenitors (CMPs), and
committed DC precursors (CDPs), all of whom express Sfpi1
and have the potential to develop into DCs (Back et al., 2005;
D’Amico and Wu, 2003; Dakic et al., 2005; Manz et al., 2001;
Naik et al., 2007; Onai et al., 2007). All precursor populations of
the Sfpi1fl/flCreERtm+ genotype showed marked reduction in
DC development in the presence of tamoxifen (Figures 3A–3C),
demonstrating a continuous requirement for PU.1 for Flt3L-
induced DC differentiation. In contrast, control cultures lacking
tamoxifen or Cre activity generated similar numbers of DCs
(Figures 3A–3C). CreERtm+ LSK cells cultured with or without
tamoxifen also generated similar number of DCs, excluding the
possibility that the lack of DC development in the absence of
PU.1 was because of a potential cytotoxic effect of tamoxifen-
induced Cre activity (Figure 3A). Taken together, these results
demonstrate a requirement of PU.1 for DC development from
DC committed, as well as multipotent progenitors.
DC development can also be induced from hematopoietic
progenitors by GM-CSF (Inaba et al., 1992). Culture of Sfpi1fl/D
CreERtm+ LSK cells in the presence of GM-CSF and IL-4 resulted
in abundant DC generation, whereas addition of tamoxifen to the
cultures abolished DC generation (Figure S2E). These data
confirm that PU.1 is essential for both Flt3L- and GM-CSF-
induced DC development from early hematopoietic progenitors.
PU.1 Is Required for the Expression of Flt3
The above results suggested that PU.1 plays an important role in
regulating DCdevelopment. As PU.1 has been shown to regulate
the expression of a number of cytokine receptors, we examined(C) PU.1-deficient or control BM cells were cultured together with equal number
surface markers Ly5.1, Ly5.2, CD11c, and CD45RA, then analyzed by flow cytom
tified as Ly5.1CD45RACD11chi and Ly5.1CD45RA+CD11cint, respectively. Th
See also Figure S1.
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precursors from PU.1-deficient mice. Flt3 was absent on
Linc-kit+ hematopoietic precursors from the BM and spleen
of PU.1-deficient (Sfpi1fl/flMx1Cre+) adult mice or on c-kit+
precursors from the livers of PU.1D/D E15.5 embryos (Figures
4A and 4B). Reduced Flt3 was also observed on PU.1+/D fetal
liver precursors (Figures 4B and 4C).
To further test whether the reduced Flt3 expression bySfpi1+/D
precursor cells has a consequence for DC development,
Lin liver cells from Sfpi1+/+ and Sfpi1+/D E15.5 embryos were
cultured with Flt3L in the presence of Ly5.1+ BM cells. The
Sfpi1+/D fetal liver cells generated significantly fewer DCs in
comparison to those derived from wild-type controls (Figures
4D and 4E). Similarly, when equal number of BM LSK cells puri-
fied from wild-type and Sfpi1+/D mice were subjected to the
same culture conditions, Sfpi1+/D LSK cells generated markedly
reduced number of DCs in comparison to those derived from
Sfpi1+/+ LSK cells (Figures 4D and 4E). The reduction in DC
numbers in LSK cultures was almost exclusively a result of
reduced cDC formation, as pDC numbers were similar between
the genotypes (Figures 4D and 4E). Within the cDC lineage, the
defect was most pronounced for the Sirpa subset (Naik et al.,
2005). Thus, PU.1 is a dose-dependent regulator of DC develop-
ment, with cDCs being the most sensitive to reduced PU.1
concentration.
To ascertain whether the reduced Flt3 concentration on
Sfpi1+/D progenitors is the cause of the altered DC production,
we examined the DC forming potential of BM cells from the
Flt3+/ mice. As expected, Lin BM cells from Flt3+/ mice
expressed approximately half the amount of Flt3 (MFI = 159.0 ±
8.5) compared to Flt3+/+ control mice (MFI = 358.7 ± 11.0). Strik-
ingly, Flt3+/ BM cells showed an almost identical defect in DC
formation to that observed with Sfpi1+/D progenitors, that is,
reduced total DC numbers with the strongest reduction coming
from the cDC compartment (Figure 4F and Figure S3).
Because it has been reported that Flt3 was also expressed by
DCs in peripheral lymphoid tissues and was important in the
homeostasis of the peripheral DCs (Karsunky et al., 2003; Liu
et al., 2009), we examined the amount of Flt3 on splenic DCs
after PU.1 inactivation. Four days after polyIC treatment (the
time point before all splenic DC were replenished), the remaining
splenic DCs in Sfpi1fl/flMx1Cre+mice showed not only a reduced
number of cDCs (0.65 ± 0.1 3 106 and 0.29 ± 0.04 3 106 per
spleen from Sfpi1fl/fl and Sfpi1fl/flMx1Cre+ mice, respectively),
but also a significantly lower surface Flt3 concentration than
that of Sfpi1fl/fl mice (Figure 4G), suggesting a role of PU.1 in
maintaining Flt3 expression by peripheral DCs.
PU.1 Directly Regulates Flt3 Expression
To test if PU.1 is directly responsible for the induction or mainte-
nance of Flt3 expression, we analyzed the interaction of PU.1
with the Flt3 regulatory elements in hematopoietic progenitors.
These studies made use of Pax5/ pro-B cells that express
abundant Flt3 because of the fact that Pax5 normally repressess of Ly5.1+ BM cells and Flt3L for 9 days. Cultured cells were stained for cell
etry. The cDC and pDC derived from PU.1-deficient or control BM were iden-
e data shown are representative of three such experiments with similar results.
Figure 3. PU.1-Deficient Progenitors Fail to Generate DCs in Flt3L Cultures
(A and B) The progenitor populations (A) LSK cells, (B) CLPs, CMPs, and CDPs, were isolated from BM of Sfpi1fl/flCreERtm+ or Sfpi1fl/fl mice. The progenitor cells
(103 LSK cells or 104 CLPs, CMPs, and CDPs) were cocultured with Ly5.1 BM feeder cells (3 3 105) in the presence of Flt3L with or without 1 mM
Immunity
PU.1 Is Required for Dendritic Cells
Immunity 32, 628–641, May 28, 2010 ª2010 Elsevier Inc. 633
Immunity
PU.1 Is Required for Dendritic Cellsthe Flt3 promoter in the B cell lineage (Holmes et al., 2006). Pax5-
deficient pro-B cells are capable of multilineage differentiation,
including to DCs, and thus represent a tractable early hemato-
poietic progenitor model to assay the regulation of Flt3 expres-
sion (Nutt et al., 1999). To specifically inactivate Sfpi1 in pro-B
cells, cultures were established from Pax5/Sfpi1fl/fl BM and
transduced with a CreER-expressing retrovirus. After short-
term Cre activation, individual colonies were genotyped for the
presence of Sfpi1 exon 5 and assayed for PU.1 protein by immu-
noblotting. This process generated both Sfpi1fl/D and Sfpi1D/D
cell lines (Figures 5A and 5B).
Inactivation of Sfpi1 resulted in the loss of Flt3, whereas
Pax5/Sfpi1fl/D cells expressed intermediate amounts of Flt3
and PU.1 (Figures 5B and 5C). Quantitative PCR confirmed the
PU.1 dosage-dependent expression of Flt3 (Figure 5D). To
determine if Flt3 could be rescued by the re-expression of
PU.1, Pax5/Sfpi1D/D pro-B cells were transduced with a retro-
viral vector encoding for an estrogen-inducible PU.1-ER protein.
Cell-surface Flt3 could be detected specifically from the PU.1-
ER-transduced cells by 24 hr after addition of b-estradiol
(Figure 5E). Kinetic analysis showed that initiation of Flt3 tran-
scription was rapid (within 4 hr of PU.1-ER induction) and
occurred in the presence of cycloheximide, suggesting that
PU.1 directly activated the Flt3 gene (Figure 5F).
To determine how PU.1 activates Flt3, we surveyed the Flt3
gene for PU.1-binding sites. The Flt3 genomic sequence of
human, mouse, and dog were aligned and searched for con-
served regions in the putative promoter and large (17kb) first
intron. Two conserved consensus PU.1-binding sites were iden-
tified in the promoter and in a conserved region of the first intron
(Figures 6A–6C). To determine whether PU.1 binds to these sites
in vivo, we performed chromatin-immunoprecipitation (ChIP)
assays. PU.1-chromatin complexes were immunoprecipitated
from Pax5/Sfpi1fl/fl cell lines using a PU.1 polyclonal antibody,
and quantitative PCR with site-specific primers was used to
analyze for enrichment of the identified sites. PU.1-deficient
(Pax5/Sfpi1D/D) pro-B cells were used as antibody specificity
control, and primers in intron 9, and a previously described
PU.1-binding site in the Il7r promoter (DeKoter et al., 2002),
acted as a negative and positive controls, respectively. Clear
PU.1 occupancy was observed for both putative binding sites,
with intermediate enrichment for the ETS site within intron 1
and strong PU.1 binding within the promoter region (Figure 6D).
Taken together, these experiments demonstrate that PU.1 regu-
lates Flt3 expression through direct interaction with conserved
regions in the Flt3 promoter and first intron and that PU.1 is
not only essential for induction but also for the maintenance of
Flt3 expression.
To examine whether Flt3 is the only crucial target of PU.1, we
attempted to rescue DC development in vivo by complementing
the PU.1-deficient progenitors with ectopic Flt3. This approach4-hydroxytamoxifen (Tam). The resulting cultures were analyzed by flow cytome
CreERtm+ and Sfpi1fl/fl mice were identified as Ly5.1CD11c+ (boxes). LSK cells
and used as control for potential cytotoxicity of tamoxifen-induced Cre activity.
(C) The number of DCs generated in each culture was calculated and presented as
itor population. To compare different experiments, the data were normalized for th
Data are themean ± SD of two such experiments. p values compare the indicated
sample equal variance t test (one-tailed) of the log-transformed average cell numb
See also Figure S2.
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cient pro-B cells (Nutt et al., 1999; Figures 6E–6G). As expected,
Pax5/Sfpi1D/D pro-B cells failed to differentiate into DC upon
in vivo transfer, despite their ability to maintain a self-renewing
pro-B cell population within the BM. Similarly, Pax5/Sfpi1D/D
pro-B cells that ectopically express amounts of Flt3 directly
comparable to Pax5/ pro-B cells also failed to form any pDC
or cDCs (Figures 6E–6G). These data suggest that PU.1 fulfills
other yet-to-be-defined functions in promoting the transcrip-
tional program of DCs beyond the initiation and maintenance
of Flt3 expression.DISCUSSION
The transcription factor PU.1 is essential for the development of
all myeloid and lymphoid lineage cells during embryonic hemato-
poiesis. A role of PU.1 in DC development has been suggested
by the analysis of germline PU.1-deficient mice. However, the
conclusions reached from these studies were conflicting and
limited by the embryonic or neonatal lethality. One study con-
cluded that PU.1 is necessary for all DC development because
Sfpi1/ neonates lacked thymic DCs and were unable to
generate DCs in vitro in response to GM-CSF (Anderson et al.,
2000), whereas a second study found that Sfpi1/ fetal thymi
could generate DCs (Guerriero et al., 2000). It is important to
note that these approaches could not distinguish between
requirements for PU.1 in multipotent progenitors, compared to
a function of PU.1 directly within the DC lineages. Moreover
the more recent development of alleles that allow the conditional
ablation of PU.1 in adult mice has revealed opposing functions of
this factor between fetal and adult myelopoiesis (Dakic et al.,
2005) and B cell development (Polli et al., 2005).
In this study, we have inducibly inactivated Sfpi1 during adult
BM hematopoiesis to determine the function of PU.1 in the DC
lineages. We have demonstrated a cell-intrinsic defect in both
cDC and pDC development in adult mice. Previous studies
have shown that the BM hematopoietic progenitors, including
HSCs, as well as myeloid and lymphoid restricted progenitors
(CMPs and CLPs), all express high amounts of Sfpi1 (Nutt
et al., 2005) and have the potential to differentiate into both
pDCs and cDCs (D’Amico and Wu, 2003; Manz et al., 2001).
To determine whether PU.1 was required for the development
of DCs from these progenitors, we have combined the Flt3L
culture system, which supported the development of DCs with
a tamoxifen-inducible Cre transgenic strain that efficiently inac-
tivated Sfpi1 in each progenitor population in vitro. Importantly,
inactivation of Sfpi1 within hematopoietic progenitors and within
DC-committed CDPs ablated DC differentiation. Thus, PU.1 is
absolutely required for DC development in vivo and in vitro in
response to Flt3L.try for Ly5.1, Ly5.2, and CD11c. The DCs derived from progenitors of Sfpi1fl/fl
isolated from Cre-ERtm+ mice were subjected to the same culture conditions
number of DCs (average of 3 to 4 wells) per indicated number of input progen-
e relative cell number of Sfpi1fl/fl cultures in the absence of tamoxifen (set as 1).
groups to the corresponding genotype in the absence of tamoxifen using a two-
er. One-tailed tests were used to assess the reliance of DC formation on PU.1.
Figure 4. Dose-Dependent Requirement of Flt3 Expression and cDC Development for PU.1
(A) BM and spleen Lin cells were isolated from Sfpi1fl/flMx1Cre+ and control Sfpi1fl/fl mice 2 weeks after polyIC treatment and analyzed by flow cytometry for
expression of Flt3 and c-kit.
(B) Erythrocyte-depleted fetal liver cells (E15.5) of the indicated genotypes were analyzed for PU.1-GFP, Flt3, and c-kit expression.
(C) The Flt3 expression by fetal liver progenitors of indicated genotypes were measured as mean fluorescent intensity (MFI). The data were normalized for the
relative MFI of Sfpi1+/+ fetal liver cells (set as 1). Data are the MFI ± SD from between three and five embryos per genotype.
(D) Sfpi1+/+ and Sfpi1+/Dgfp fetal liver and adult BM LSK cells were cocultured with Ly5.1+ BM feeder cells in the presence of Flt3L for 9 days and analyzed for the
expression of CD11c, Ly5.1, CD45RA, and Sirpa (CD172a) by flow cytometry. Right panels show gated CD11c+Ly5.1 cells.
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PU.1 Is Required for Dendritic CellsFlt3 shows a dynamic expression profile, being initially
induced on short-term repopulating HSCs, also termed multipo-
tent progenitors (MPPs). An increased concentration of Flt3
is then found on lymphoid-primed multipotent progenitors
(LMPPs) and is maintained on CLPs (Adolfsson et al., 2005).
Flt3 expression is then extinguished in most hematopoietic line-
ages, with the exception of DCs (Kingston et al., 2009). The pres-
ence of Flt3 on these precursor cells has been shown to correlate
exactly with their ability to differentiate into DCs in steady state
(D’Amico and Wu, 2003; Karsunky et al., 2003). Although Flt3
plays an important role in LMPPs (Sitnicka et al., 2007) and
CLPs (Sitnicka et al., 2002), there is conflicting data as to its
importance for the earliest stages of DC development in vivo
(Kingston et al., 2009; Waskow et al., 2008). Flt3 is, however,
essential for normal peripheral DC homeostasis (Kingston
et al., 2009; Waskow et al., 2008).
Despite its importance in early hematopoiesis and DC devel-
opment, there is surprisingly little known about how Flt3 expres-
sion is controlled. LMPPs isolated from mice lacking the
transcription factor Ikaros have reduced Flt3 expression sug-
gesting that this factor plays a role; however, the molecular
mechanism for this remains unknown (Yoshida et al., 2006).
Here, we have shown an essential and direct role for PU.1 in
regulating Flt3 expression in multipotent hematopoietic precur-
sors and have demonstrated that PU.1-deficient progenitors
are incapable of generating DCs in response to Flt3L. The
requirement of Flt3 for PU.1 is absolute as all PU.1-deficient fetal
and adult hematopoietic progenitors lack Flt3. The relationship
of PU.1 and Flt3 appears to be reciprocal because ectopic
expression of Flt3 in megakaryocyte-erythrocyte restricted pro-
genitors (MEPs) induced Sfpi1 and DC differentiation, whereas
enforced expression of Sfpi1 in MEPs in turn led to the upregu-
lation of Flt3 (Onai et al., 2006). In addition to the important role
of PU.1 in regulating Flt3 expression by early progenitors, our
study also demonstrated that PU.1 maintained Flt3 expression
in already-formed DCs in peripheral lymphoid tissue as a signifi-
cant reduction in the surface Flt3 amounts on PU.1-deficient
splenic DCs was observed.
Although absence of Flt3 on PU.1-deficient cells has important
consequences for early hematopoiesis and DC development,
PU.1 is likely to have many important targets in DCs because it
has already been shown to regulate a large number of myeloid
genes, including those encoding integrins (CD11b), granule
proteins such as myeloperoxidase, and cytokine receptors
(reviewed in Dakic et al., 2007; Tenen et al., 1997). Indeed,
PU.1 was also essential for GM-CSF-induced DC development
from hematopoietic progenitors. As the gene encoding the
GM-CSFRa chain (Csf2ra) is a known PU.1 target gene (Hohaus
et al., 1995), these findings suggest that PU.1 is required for the
complementary functions of GM-CSFR and Flt3 in supporting(E) The number of DCs of each phenotype generated in fetal liver or LSK cell cultur
per 5 3 103 input LSK cells (average of 3 wells). The data are representative of t
(F) The number of DCs generated from total BM cells (1.53 106) of Flt3+/ and Flt3
(F) compare the indicated groups using a two-sample equal variance t test (one-ta
assess the reliance of DC formation on PU.1.
(G) Flt3 expression by splenic cDCs isolated from Sfpi1fl/fl and Sfpi1fl/flMx1cre+mi
compare the indicated groups using a two-sample equal variance t test (one-tail
See also Figure S3.
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it is not surprising that our attempts to rescue DC development
from PU.1-deficient progenitors by complementation with Flt3
have proved unsuccessful. While the identity of the other key
targets of PU.1 in DCs will be the subject of future experimenta-
tion, it is also likely that PU.1 regulates a distinct set of target
genes in pDC and cDC subsets because mice lacking either
IRF-8 or IRF-4, factors that frequently, but not exclusively,
interact with PU.1, have distinct and DC subset specific defects
(Merad and Manz, 2009).
A large number of studies have concluded that the concentra-
tion of PU.1 is critical for hematopoietic cell-fate determination
and to suppress leukemia (Anderson et al., 2002; Bakri et al.,
2005; Dahl et al., 2003; DeKoter and Singh, 2000; Laiosa et al.,
2006; Rosenbauer et al., 2004; Ye et al., 2005). The majority of
these studies used overexpression of Sfpi1, although the effects
of lowering PU.1 concentration by 50%–90%have also been ad-
dressed (Houston et al., 2007; Rosenbauer et al., 2004). Within
the DC lineage, Sfpi1 is highly expressed in CDPs and cDCs
and is downregulated at the onset of pDC differentiation.
Whether this downregulation is essential for pDC commitment
remains to be explored. Although the consequence of altering
PU.1 concentrations on cell-fate determination is striking, how
distinct concentrations of PU.1 are distinguished on a molecular
level has been more difficult to determine, but they may include
direct protein-protein antagonism in the manner of the PU.1-
GATA interaction (Huang et al., 2007) or a regulatory circuit
involving the expression of antagonistic repressors (Spooner
et al., 2009). Surprisingly, given the above-mentioned body of
work, there has been little evidence of functional or molecular
haploinsufficiency in Sfpi1+/mice. Although Sfpi1+/ embryonic
stem cells as well as Sfpi1+/Csf3/ mice produce more gran-
ulocytes, this effect was interpreted as a consequence of an
antagonistic relationship between PU.1 and C/EBPa, and no
dose-sensitive target genes were found (Dahl et al., 2003). In
the present study, we have found that the loss of one Sfpi1 allele
impaired DC production in Flt3L cultures and that this reduction
is exclusive to the cDCs, demonstrating that those DCs that
were most sensitive to PU.1 dosage are those that normally
contain the most PU.1 protein. Strikingly, the haploinsufficiency
extended to Flt3 expression that was reduced to approximately
half in Sfpi1+/D progenitors. This reduced Flt3 concentration was
important because Flt3+/BM cells generated less cDCs in Flt3L
cultures than that of Flt3+/+ controls, an almost identical pattern
to that obtained with Sfpi1+/ precursors. Thus, the Flt3 gene
provides one of the best examples yet identified of a PU.1 dose-
sensitive target gene that has a functional consequence for
hematopoietic cell development.
Research in the last decade has revealed the intricate
network of cellular subsets and differentiation states thates was calculated as the mean DC number ± SD per 105 input fetal liver cells or
wo similar experiments.
+/+mice. Data are the mean ± SD of fivemice per genotype. p values for (E) and
iled) of the log-transformed average cell number. One-tailed tests were used to
ce 4 days post-polyIC treatment. Data are the MFI ± SD. p values for (C) and (G)
ed).
Figure 5. PU.1 Regulates the Expression of Flt3
(A) Pax5/Sfpi1fl-gfp/fl-gfp pro-B cell lines (termed Pax5/Sfpi1fl/fl for simplicity) were transduced with a CreERtm expressing retrovirus. Cre activity was induced
with 1 mM 4-hydroxytamoxifen (Tam) and clones were produced by limiting dilution. The excision of the floxed Sfpi1 exon 5 (fl) to create the D allele was deter-
mined by PCR. Nine representative clones generated in the presence of tamoxifen (+ Tam) and two parental control clones (no Tam) are shown.
(B) PU.1 protein level was determined for the same clones assayed in (A).
(C and D) Flt3 protein (C) and mRNA (D) amounts was determined from Pax5/Sfpi1fl/fl (n = 4), Pax5/Sfpi1fl/D (n = 5), and Pax5/Sfpi1D/D (n = 5) pro-B cell
clones derived as for (A), by flow cytometry and real-time PCR, respectively. Data in (D) include wild-type pro-B cells (+/+) and represent the mean ± SD.
(E and F) Re-expression of PU.1 induces Flt3 expression. Pax5/Sfpi1D/D pro-B cells were transduced with an estrogen-inducible PU.1-ER vector. Induction of
PU.1 function by 1 mM b-estradiol resulted in the re-expression of Flt3, as measured by flow cytometry (E) and real-time PCR (F). The induction of Flt3 by PU.1-ER
was not affected by the presence of cycloheximide (CHX). Data in (E) are representative of three independent experiments. Data in (F) are the mean ± SD and are
representative of two experiments analyzed in triplicate. p values compare the indicated groups using a paired t test (two-tailed).
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2007). This complexity is programmed by the singular and com-
binatorial action of a network of transcription factors, including
Irf8, Irf4, RelB, Batf3, E2-2, Id2, Ikaros, Gfi-1, STAT3, and
STAT5, which are involved in the development of specific DC
populations (Merad and Manz, 2009). PU.1, in contrast, is intrin-sically required for all DC lineages. The regulation of the essen-
tial cytokine receptors, Flt3 and GM-CSFR by PU.1, as well as
the previously reported ability of PU.1 to reprogram thymic
progenitors to DCs (Laiosa et al., 2006), demonstrates that
PU.1 is both necessary and sufficient for the development of
all DC lineages.Immunity 32, 628–641, May 28, 2010 ª2010 Elsevier Inc. 637
Figure 6. Direct Binding of PU.1 to the Flt3 Regulatory Regions
(A) Genomic structure of mouse Flt3 with exons depicted as boxes. Only exons 1–10 of the total of 24 are shown. Inset depicts regions of conservation with the
Flt3 genes from human and dog; exons and conserved non-coding sites (CNS) are shaded. Sequence analysis was performed using the mVista program. Arrows
indicate the location of the Flt3 promoter, intron 1, and control primers (intron 9) used in the ChIP analysis.
(B and C) Sequence alignment of the mouse and human Flt3 genes, showing the promoter region (B) and the CNS within intron 1 (C). Conserved nucleotides are
highlighted by a black background. PU.1 binding sites predicted by the Jaspar algorithm are boxed.
(D) Binding of PU.1 within the Flt3 gene was analyzed using ChIP and real-time PCR on Pax5/Sfpi1fl/fl (n = 3) and Pax5/Sfpi1D/D (n = 2) clones. Data are the
mean percentage input ± SD. Primers flanked the Flt3 intron 9 (control) and the ets sites in Flt3 intron 1 and the Flt3 promoter (prom.) as depicted in (A). The ets site
in the Il7r promoter was a positive control.
(E and F) Flow cytometric analysis of (E) BM cells and (F) spleen DC preparation from sublethally irradiated C57Bl/6Ly5.1 mice injected with 13 106 pro-B cells of
the genotypes Pax5/Sfpi1fl-gfp/fl-gfp (termed Pax5/), Pax5/Sfpi1Dgfp/Dgfp (termed Pax5/Sfpi1D/D), and Pax5/Sfpi1Dgfp/DgfpFlt3 (pro-B cells transduced
with a Flt3 expressing retrovirus, termed Pax5/Sfpi1D/DFlt3). Donor-derived (GFP+) cells were detected after 4–12 weeks. For (F), cDC and pDC were distin-
guished by CD11c and 120G8 expression. Numbers indicate the proportion of cells in the adjacent boxes.
(G) Quantification of the splenic cDC and pDC numbers of mice injected with pro-B cells as described in (E). Each data point represents a single recipient mouse.
The mean is indicated by a horizontal line.
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PU.1 Is Required for Dendritic CellsEXPERIMENTAL PROCEDURES
Mice
The Sfpi1fl-gfp (floxed allele that also contains GFP knockin into the Sfpi1 30
untranslated region) and Sfpi1fl/fl (Sfpi1floxed allele) and Sfpi1fl/flMx1Cre mice
were generated by our group previously (Dakic et al., 2005; Nutt et al., 2005).
Note the excision of Sfpi1 exon 5 by Cre recombinase from Sfpi1fl-gfp/fl-gfp and
Sfpi1fl/fl mice results in the generation of Sfpi1D-gfp/D-gfp, Sfpi1fl/D, and Sfpi1D/D
alleles, respectively. Sfpi1fl/flCreERtm mice were produced by crossing the
Sfpi1fl/fl mice with B6.Cg-Tg (cre/Esr1) 5Amc/J transgenic mice from The
Jackson laboratory (Hayashi and McMahon, 2002). vav-Bcl-2 transgenic
(Ogilvy et al., 1999) and Flt3+/ (Mackarehtschian et al., 1995) mice have
been previously described. For conditional inactivation in vivo, Sfpi1fl/flMx1Cre
mice were injected i.p. with 12.5 mg/g polyIC (GE Healthcare) two times at
3 day intervals, then used 4–14 days after the first injection. Genotyping to
assess the frequency of Sfpi1 exon 5 excision and BM chimeras were per-
formed as previously described (Dakic et al., 2005). Mice were bred and main-
tained at the Walter and Eliza Hall Institute under Animal Ethics Committee
guidelines.
Monoclonal Antibodies and Flow Cytometry
The monoclonal antibodies used for flow cytometry are described in Supple-
mental Experimental Procedures.
DC Isolation
The cDCs and pDCs were enriched from thymus or spleen by digesting the
tissue fragments with collagenase and DNase, followed by light density sepa-
ration and then immunomagnetic bead depletion using the procedure
described elsewhere (Vremec et al., 2000). These cDC and pDC–enriched
preparations were then stained in four fluorescent colors using conjugated
antibodies to CD11c and MHC-II (pan-DC markers); CD45RA (for pDCs);
and CD4, CD8a, and CD205 (cDC subsets).
Isolation of Bone Marrow Precursor Populations
TheBMprecursorpopulationswere isolatedbyprocedures thatweredescribed
in detail elsewhere (Manz et al., 2001; Wu et al., 2001). LSK cells were defined
as LinSca-1hiIL-7Rac-kithi, CLPs as LinSca-1intIL-7Ra+c-kitint, CMPs as
LinSca-1IL-7Rac-kit+CD34+FcgRlo, and CDPs as LinIL-7RaCD11c
c-kitloCD115+Flt3+FcgRlo cells (Naik et al., 2007; Onai et al., 2007).
DC Cultures
Erythrocyte-depleted fetal liver or adult BM cells (1.5 3 106/ml), or purified
progenitor populations (13 103–104/well in 96-well culture plate) were cultured
with Ly5.1+ BM feeder cells (1.5 3 106/ml or 1.5 3 105/well in 96-well culture
plate) in the presence of murine Flt3L (200 ng/ml) as previously described
(Naik et al., 2005). For PU.1 inactivation in culture, 1 mM 4-hydroxytamoxifen
(Sigma-Aldrich) was added to each well on day 0. Cells were cultured for
9 days, then harvested and stained with fluorescence-conjugated mAbs to
Ly5.1 and DC surface markers, including CD11c, CD45RA, CD11b, 120G8,
and CD172a. In some experiments, LSK cells (1 3 104) were cultured with
Ly5.1 BM feeder cells (1 3 105/well), with mGM-CSF (20 ng/ml) and mIL-4
(20 ng/ml, both from PeproTech Inc.) as described elsewhere (Inaba et al.,
1992). Cells were harvested 5 days later and stained as for the Flt3L cultures.
Retrovirus Production and Infection
Retroviral supernatants were generated by transient transfection of 293T cells
with plasmids encoding viral envelope proteins (pMD1-gag-pol and pCAG-
Eco), and expression vectors encoding for pMIG-iresGFP, pMIG-PU.1-ER-
iresGFP, pMIG-Flt3-iresGFP (Holmes et al., 2006), or pMIG-CreERtm-ires-
human CD4 using calcium phosphate precipitation (CalPhos Mammalian
Transfection Kit, Clontech). Retroviral supernatants were centrifuged onto
RetroNectin (Takara)-coated plates for 45 min at 4000 rpm at 4C. Cells
were then cultivated with the virus in the presence of 4 mg/ml polybrene
(Sigma-Aldrich) for 12 hr.
Generation and Analysis of PU.1-Deficient Pro-B Cell Lines
Pro-B cell cultures were derived from Pax5/Sfpi1fl-gfp/fl-gfp BM as described
(Carotta et al., 2006). To induce the deletion of Sfpi1 exon 5, pro-B cells weretransduced with the retroviral vector pMIG-CreERtmires-humanCD4. Trans-
duced CD4+ cells were isolated via flow cytometric sorting and Cre activity
induced by addition of 1 mMof 4-hydroxytamoxifen for 48 hr. Single-cell clones
were established through limiting dilution. To confirm deletion of Sfpi1 exon 5,
DNA and protein extracts from individual clones were screened by PCR gen-
otyping or immunoblotting, respectively, as described (Dakic et al., 2005).
Immunoblotting was performed using anti-PU.1 (T-21) and anti-b-actin
(I-19), both from Santa Cruz. The PU.1-ER retrovirus was introduced into
Pax5/Sfpi1D-gfp/D-gfp pro-B cells as described above and induced by the
addition of 1 mM b-estradiol. Some experiments were performed in the
presence of 50 mg/ml cycloheximide (Sigma-Aldrich). For the in vivo rescue
experiments, Pax5/Sfpi1D-gfp/D-gfp pro-B cells were transduced with
pMIG-Flt3-iresGFP and FACS sorted on the basis of Flt3 expression. 1 3 106
Pax5/Sfpi1fl-gfp/fl-gfp, Pax5/Sfpi1D-gfp/D-gfp, and Pax5/Sfpi1D-gfp/D-gfp
Flt3+ pro-B cells were transferred into sublethally irradiated C57Bl/6 Ly5.1 or
Rag2/cg/ mice and analyzed after 4–12 weeks.
Real-Time PCR and ChIP Assays
RNA was isolated using TRIzol (Invitrogen), and cDNA was synthesized from
total RNA with an oligo-dT primer using Superscript III Reverse Transcriptase
(Invitrogen). Quantification of Flt3 expression was performed using Taqman
gene expression assays (Flt3: Mm00439016_m1, HPRT: Mm01545399_m1).
ChIP was performed on 5 3 107 Pax5/Sfpi1fl-gfp/fl-gfp and Pax5/
Sfpi1D-gfp/D-gfp pro-B cells with 10 mg anti-PU.1 antibody (T-21) as described
(Boyer et al., 2006). To measure enrichment, quantitative PCR was performed
with primers listed in Supplemental Experimental Procedures. Standard
curves were generated from serial dilutions of whole-cell extract DNA. Reac-
tions were performed in triplicate with SYBR green PCR master mix (Invitro-
gen) on an ABI 7900HT machine.
Statistical Analysis
The statistical significance of the differences in the mean ± SD was calculated
using a Student’s t test as indicated in the figure legend.SUPPLEMENTAL INFORMATION
The Supplemental Information includes three figures and Supplemental
Experimental Procedures and can be found with this article online at doi:10.
1016/j.immuni.2010.05.005.
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